New Appropriate Use Criteria Issued for Valvular Heart Disease

Share this content:
New Appropriate Use Criteria Issued  for Valvular Heart Disease
New Appropriate Use Criteria Issued for Valvular Heart Disease

TUESDAY, Sept. 5, 2017 (HealthDay News) -- Appropriate use criteria have been developed for valvular heart disease imaging tests, according to a report published online Sept. 1 in the Journal of the American College of Cardiology.

John U. Doherty, M.D., from Thomas Jefferson University, and colleagues discussed appropriate use criteria to address the evaluation and use of multimodality imaging in the diagnosis and management of valvular heart disease.

The authors address the appropriate use of multiple imaging modalities available for clinicians in the evaluation of valvular heart disease, discussing the spectrum of patients, from asymptomatic patients to those with symptoms ranging from moderate to severe. Different categories of indications were created using a standardized approach with a goal of capturing real-world clinical scenarios. The clinical scenarios were rated by an independent panel, which determined whether use of an imaging test for each indication should be classified as "appropriate," with benefits outweighing risks; "may be appropriate, " with variable evidence or agreement regarding the benefit-risk ratio; or "rarely appropriate, " with lack of a clear benefit/risk advantage. Clinical opinions may vary for a specific scenario; even appropriate tests may not always be necessary depending on physician judgment and patient-specific preferences.

"As imaging technologies and clinical applications continue to advance, the health care community must understand how best to incorporate these technologies into daily clinical care and how to choose between new and established imaging technologies," the authors write.

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »